Seroprevalence of human T-lymphotropic virus (HTLV) in blood donors in sub-Saharan Africa: a systematic review and meta-analysis.

Autor: Ngoma AM; Douglas Hospital Research Centre, McGill University, Montreal, QC, Canada., Omokoko MD; Hôpital de la Cité-de-la-Santé, Affiliated to the University of Montreal, Montreal, QC, Canada., Mutombo PB; School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo., Nollet KE; Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan.; Radiation Medical Science Center, Fukushima Medical University, Fukushima, Japan., Ohto H; Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan.; Radiation Medical Science Center, Fukushima Medical University, Fukushima, Japan.
Jazyk: angličtina
Zdroj: Vox sanguinis [Vox Sang] 2019 Jul; Vol. 114 (5), pp. 413-425. Date of Electronic Publication: 2019 Apr 11.
DOI: 10.1111/vox.12779
Abstrakt: Background and Objective: Human T-cell lymphotropic viruses (HTLV) 1 and 2 are endemic in sub-Saharan Africa (SSA), transfusion-transmissible and causally linked to various severe diseases. However, even in SSA countries with moderate to high endemicity, routine blood donor screening for HTLV is rarely, if ever, performed. Information on seroprevalence is limited. The aim of this review is to establish the prevalence of HTLV-1 and HTLV-1/2 among blood donors in sub-Saharan Africa.
Materials and Methods: We systematically reviewed databases including EMBASE, MEDLINE and the Cochrane database library from their inception to June 2018. Studies presenting data on HTLV prevalence among blood donors in sub-Saharan Africa were included. A random-effect meta-analysis was conducted on all eligible studies.
Results: A total of 25 studies were included, representing 74 119 blood donors, of whom over 80% (61 002) were only tested for HTLV-1. The evidence base was high and moderate in quality. The pooled prevalence of the 17 studies that screened only for HTLV-1 and the nine studies that screened for HTLV-1/2 was 0·68 (95% CI: 0·29-1·60) and 1·11 (95% CI: 0·47-2·59) per 100 blood donors, respectively.
Conclusion: The prevalence of HTLV-1 infection among blood donors is relatively low. The current review is intended to inform debates and decisions about best practices to prevent transfusion-transmitted HTLV in sub-Saharan Africa. Further work is required to determine the risk of infections by transfusion and the cost-effectiveness of any new measures such as routine screening.
(© 2019 International Society of Blood Transfusion.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje